IRESSA 250 (Iressa 250 mg)
Generic Name: gefitinib
Pill imprint IRESSA 250 has been identified as Iressa 250 mg.
Iressa is used in the treatment of non-small cell lung cancer and belongs to the drug class EGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Iressa 250 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Generic Name:
- gefitinib
- Imprint:
- IRESSA 250
- Strength:
- 250 mg
- Color:
- Brown
- Size:
- 11.00 mm
- Shape:
- Round
- Availability:
- Prescription only
- Drug Class:
- EGFR inhibitors
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- AstraZeneca Pharmaceuticals
- National Drug Code (NDC):
- 00310-0482
- Inactive Ingredients:
- lactose monohydrate
microcrystalline cellulose
croscarmellose sodium
povidone
sodium lauryl sulfate
magnesium stearate
hypromelloses
polyethylene glycol 300
titanium dioxide
ferric oxide red
ferric oxide yellow
Note: Inactive ingredients may vary.
More about Iressa (gefitinib)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 7 Reviews – Add your own review/rating
- Drug class: EGFR inhibitors
Consumer resources
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2017 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
